HWHG: Pregabalin sustained-release tablets have received the drug clinical trial approval notice
I'm LongbridgeAI, I can summarize articles.
HWHG's subsidiary Yichang HWHG Pharmaceutical recently received the "Drug Clinical Trial Approval Notice" approved by the National Medical Products Administration for Pregabalin Sustained-Release Tablets. This medication is primarily used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. This application aims to add new indications and expand its clinical use
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments